The Effects of Losartan on Attention Control: An Eye-tracking Study

Not Applicable

Recruiting

• Conditions: Healthy
• Interventions: Drug: Losartan; Drug: Placebo

• Registration Number: NCT06329050
• Lead Sponsor: University of Electronic Science and Technology of China

Brief Summary

The main aim of the present study is to investigate the effects of orally administered Losartan on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Detailed Description

Animal models and initial findings in humans suggest that the angiotensin II antagonist Losartan may have neuroprotective effects and could potentially enhance cognitive functions, including valence-specific attention and regulatory control. Within this context the present study aims to examine whether angiotensin II blockade via Losartan modulates top-down and bottom-up attentional control towards socio-affective stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of Losartan (50 mg) or placebo before performing a saccade/anti-saccade task 90 minutes after administration. The task paradigm will encompass social (happy, angry, fearful, sad and neutral faces) and non-social (oval) stimuli to examine general as well as social and emotion-specific effects of oral losartan.

Study Timeline

• Study Start: 2024-03-05
• Study First Submitted: 2024-03-15
• Study First Submitted QC: 2024-03-15
• Study First Posted: 2024-03-25
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-09
• Last Update Posted: 2024-04-11
• Primary Completion: 2025-06-01
• Study Completion: 2025-07-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.

Normal or corrected-normal version

Exclusion Criteria

• History of neuropsychiatric diseases.
• History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
• History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
• History of renal diseases, including renal stones or renal failure.
• History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
• Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
• Infections such as COVID-19 or influenza, or unexplained fever.
• Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
• History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
• Blood donation (≤ 1 month prior to administration).
• Take oral contraceptives or receive hormonal medications in the three months prior to the experiment.
• Pregnant or breastfeeding.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Losartan group	Losartan	Losartan tablet(50 mg)
Placebo group	Placebo	Placebo tablet

Primary Outcome Measures

Name	Time	Method
Saccade/antisaccade latency difference between social and non-social stimuli after losartan administration	90 minutes - 120 minutes after treatment	Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the losartan and placebo treatment conditions.
Error rate of saccade/antisaccade for social versus non-social stimuli after losartan administration	90 minutes - 120minutes after treatment	Comparison between social-specific error rates of saccade/antisaccade between the losartan and placebo treatment conditions.

Secondary Outcome Measures

Name	Time	Method
Saccade/antisaccade latency for different facial emotions after losartan administration	90 minutes - 120 minutes after treatment	Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the losartan and placebo treatment conditions.
Error rate of saccade/antisaccade for different facial emotions after losartan administration	90 minutes - 120 minutes after treatment	Comparison between emotion-specific saccade/antisaccade error rates between the losartan and placebo treatment conditions.

Trial Locations

Locations (1)

University of Electronic Science and Technology of China; 🇨🇳 Chengdu, Sichuan, China